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severe comorbidities. Comorbidities in FM are similar to 
those of other patients, but they receive more drugs and for 
a longer period of time. Drugs for nervous system comor-
bidities are introduced later, when other somatic symptoms 
are already treated. In patients with FM the treatments for 
mild comorbidities are not well justified.
Keywords Fibromyalgia · Comorbidity · Drug treatment · 
Prescription appropriateness
Introduction
It is widely known that fibromyalgia (FM) is a condition 
with numerous symptoms that virtually involve any organ 
or system [1]. The term comorbidity is used when “more 
than one disease or condition is present in the same person 
at the same time” [2]. Therefore, all those clinical condi-
tions associated with FM may be considered as comor-
bidities. Some studies have shown that FM is one of the 
rheumatic diseases with a greater number of comorbidi-
ties—more than systemic lupus erythematosus or rheuma-
toid arthritis [3, 4]—and that it produces a considerable 
impairment in the quality of life [5].
In addition, it has been shown that the association of 
multiple chronic clinical conditions in the same patient is 
very frequent and that the consequences are more impor-
tant than the simple addition of separate conditions [6]. 
Managing this situation effectively requires a multidiscipli-
nary approach for treating all the problems together rather 
than separately. A recent study [7] describes the problem 
of multiple clinical conditions in FM with seven or more 
chronic conditions in each patient. The study also high-
lights the risk of polypharmacy and the possibility of an 
impairment of clinical symptoms due to drug interactions.
Abstract The objectives of this study are to describe 
appropriateness and drug treatment of comorbidities in 
fibromyalgia (FM). Cross-sectional study of a group of 
patients. Number of drugs, indication, duration and appro-
priateness of prescriptions were evaluated. Patients were 
classified as: group 1, (FM/FM) previous FM diagnosis and 
fulfilling criteria; group 2, (noFM/noFM) other diagnosis 
and not fulfilling criteria; and group 3, (noFM/FM) other 
diagnosis but fulfilling criteria. Drugs were classified into 
drugs for nervous system, analgesics/NSAID and drugs for 
other comorbidities. Appropriateness was evaluated follow-
ing clinical therapeutic guidelines. A total of 159 patients 
were included in the study and classified into group 1, with 
59 patients; group 2, with 67 patients; and group 3, with 
33 patients. Group 1 received a greater number of differ-
ent drugs and for a longer period of time, there were less 
severe comorbidities and more unjustified treatments. No 
difference was found between the other two groups. Major 
opioids were only consumed in group 1. Also, in group 
1, 45.8 % of patients were attended in psychiatry versus 
15.6 % in group 3 and 3 % in group 2. The number of 
somatic symptoms correlated significantly with the number 
of drugs. Nervous system treatments were of shorter dura-
tion than other drug treatments. There was no difference in 
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Most symptoms present in patients with FM are very 
common and may be seen with or without the diagnosis 
of FM [8]. However, it is unknown whether FM diagnosis 
determines the treatment of these symptoms [9].
To explain this polymedication in patients with FM, we 
have hypothesized if the types of comorbidities, the drugs 
used for treating them and the appropriateness of these 
drugs are different in FM in comparison with other patients.
The analysis of the drugs used for treating FM patients 
may be considered as an estimation of the number of asso-
ciated comorbidities. It also allows to assess the importance 
of the comorbidity as well as the impact on the disease. In 
addition, assessing the appropriateness of the prescribed 
drugs may be very useful to reduce the number of drugs 
and the risk of interactions and adverse events.
The aims of this study are the following: first, to describe 
the drugs prescribed for treating all the comorbidities pre-
sent in FM patients and, second, to evaluate the appropri-





The study was performed in a Rheumatology Clinic in 
the Comunidad Autónoma of Madrid (Spain). This clinic 
attends all types of rheumatic diseases and is also a refer-
ence centre for FM patients.
Patients consecutively referred from general practition-
ers for the first time were considered for the study. Patients 
with malignancies, infectious or inflammatory diseases that 
might affect clinical manifestations were discharged. Only 
18–65-year-old native Spanish women who had given their 
informed consent were included in the study.
Drugs prescription and data collection
Clinical records—both of primary care and specialized 
medicine—were retrieved and registered through HORUS 
(a sanitary management program of the Comunidad 
Autónoma of Madrid), as well as the number of drugs pre-
scribed and the duration of the treatment at the moment 
of their first visit. Patients were divided into three groups 
according to whether they had a diagnosis of FM or ful-
filled ACR classification criteria [10] for FM as follows:
•	 Group 1 (FM/FM). Patients referred with a previous 
diagnosis of FM and also fulfilling ACR criteria.
•	 Group 2 (noFM/noFM). Patients referred with other 
diagnosis different from FM and not fulfilling ACR cri-
teria.
•	 Group 3 (noFM/FM). Patients referred with other diag-
nosis different from FM but fulfilling ACR criteria.
Only drugs prescribed by a physician were considered for 
the study. Herbal drugs and other pharmaceuticals remedies 
were not included. The duration in months from the begin-
ning of the treatment was quantified with the exception 
of NSAID and common analgesics because they are pre-
scribed by multiple reasons and used on demand.
Different drugs for treating all comorbidities were clas-
sified within three categories:
(A) Drugs for nervous system (NS) comorbidities. Pre-
scribed for any NS symptoms, sleep disorders or 
psychiatric diseases. These include antidepressants, 
anticonvulsants, benzodiazepines, hypnotics, antipsy-
chotics and dopaminergic agonists.
(B) Analgesics and nonsteroidal anti-inflammatory drugs 
(NSAID). Analgesics were divided into common 
analgesics such as paracetamol, metamizole and ibu-
profen; minor opioids such as tramadol and codeine, 
and major opioids that include fentanyl, tapentadol, 
oxycodone, buprenorphine and morphine. Although 
metamizole and ibuprofen are NSAID, they are usu-
ally indicated for analgesia.
(C) Drugs and supplements for treating other comor-
bidities. Herein were included the remaining drugs. 
Although continuous positive airway pressure (CPAP) 
is not a drug, it is the main therapeutic measure for 
treating sleep apnoea and was included in this cat-
egory.
To evaluate the appropriateness of a drug treatment, clini-
cal therapeutical guidelines frequently used in Spain were 
employed. Thus, the following drug treatments were 
assessed: lipid alterations [11], high blood pressure [12], 
osteoporosis [13], diabetes mellitus [14] and hypothy-
roidism [15]. To evaluate the appropriateness of a gluten-
free diet, an intestinal biopsy with presence of MARSH 
3 alterations was required [16]. For a lactose intolerance, 
the presence of alterations in any of the tests used to diag-
nose this entity (hydrogen test, faecal acidosis or intestinal 
biopsy) was required. For using CPAP, the presence of noc-
turnal apnoea demonstrated in a sleep laboratory analysis 
was required. The necessity of coenzyme Q10 supplements 
was established if muscular biopsy was compatible with 
this deficit.
In vitamin D, B12, other vitamins, iron and folic acid 
deficiencies, low serum levels were required to evaluate the 
appropriateness of supplementation.
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In those treatments mostly depending on the facultative 
criteria to initiate the drug treatment, the appropriateness of 
the drug was not evaluated. These included drugs for treat-
ing FM, any type of NS comorbidities, gastric protectors, 
analgesics and NSAID.
Among those comorbidities in which it was possible to 
evaluate the appropriateness of the treatment, comorbidities 
were classified as severe or mild following the research-
ers’ criteria. Hypercholesterolaemia, high blood pressure, 
osteoporosis, diabetes mellitus, hypothyroidism and sleep 
apnoea were considered as severe due to frequent and 
important complications such as cardiovascular events, 
fracture, metabolic decompensations or sudden death. 
However, vitamin D, other vitamins, iron, folic acid or Q10 
deficiencies, coeliac disease and lactose intolerance were 
considered as mild comorbidities because complications 
are seen more rarely.
Statistical analysis
Nominal values were described by means of a frequency 
analysis, and continuous variables were described with the 
mean and the standard deviation. Level of significance was 
considered at p < .05.
To compare differences between groups, a Chi-square 
test was used for nominal variables and analysis of the vari-
ance for continuous variables. Bonferroni correction was 
used for the post hoc analysis for comparing differences 
between two groups.
Pearson correlation coefficient was used for analy-
sis of correlation between continuous variables and rho 
Spearman correlation coefficient for non-parametric 
correlations.
Results
Between May and December 2015, a total of 353 patients 
were consecutively referred at the Rheumatology Clinic. 
One-hundred and ninety-four were excluded from the study 
for the following reasons: older than 65 years, 100; males, 
53; foreigners, 26; inflammatory diseases, 5; malignancies, 
5, and infectious diseases, 5 patients.
A total of 159 patients satisfied inclusion criteria for the 
study. Sixty patients were previously diagnosed of FM and 
were referred for treatment and control of the disease, and 
99 patients were referred for study, none of which had been 
previously diagnosed of FM.
After applying ACR 2010 classification criteria, patients 
were split into three groups, as shown on Table 1. One 
patient with a previous diagnosis of FM did not fulfil ACR 
criteria at the first visit and was not included in the analysis.
Final diagnoses in the patients of group 2 were as fol-
low: osteoarthritis at different locations, 34; osteoporosis, 
20; acute lumbalgia, 4; tendonitis, 2; primary Raynaud, 2; 
muscular spasms, 2; skin psoriasis, 1; metatarsal fracture, 
1; and discal herniation, 1. Variables conforming ACR cri-
teria were different between groups with greater scores in 
group 1 followed by group 3 and group 2 (Table 1).
There was a significant difference between groups in the 
total number of drugs consumed.
A significant positive correlation was found between the 
number of somatic symptoms and the number of drugs con-
sumed (r = 0.622, p < .001). A weakly but significant cor-
relation was also found between the age and the number of 
drugs consumed (r = 0.187, p = .018).
With respect to drugs used for treating NS comorbidity, 
there was a significant difference between groups in the 
Table 1  Groups of patients after applying ACR 2010 classification criteria [10]. Variables conforming criteria, age and the total number of drugs 
consumed by the patients on first visit
Group 1 (FM/FM): diagnosis of FM and fulfilling ACR criteria; group 2 (noFM/noFM): other diagnosis and not fulfilling ACR criteria; group 3 
(noFM/FM): other diagnosis and fulfilling ACR criteria
(¶) Variables conforming ACR 2010 criteria and score range
Post hoc analysis: (a) significant difference between groups 1 and 2; (b) significant difference between groups 2 and 3; (c) significant difference 












Number of patients 59 67 32 –
Pain index (0–19)(¶) 14.54 ± 3.43(a) 4.63 ± 2.54(b) 10.19 ± 3.26(c) <.001
Symptoms severity (0–12)(¶) 7.32 ± 1.47(a) 3.06 ± 1.64(b) 6.03 ± 1.63(b) <.001
Somatic symptoms (0–41)(¶) 20.46 ± 5.98(a) 4.61 ± 1.99(b) 13.50 ± 4.71(c) <.001
Age (yrs.) 48.07 ± 9.29(a) 52.36 ± 9.64 49.44 ± 8.79 <.035
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total number of drugs consumed, as well as for all types of 
NS drugs, with the exception of antipsychotics (Table 2).
In group 1, 86.4 % of the patients received any type of 
NS drugs versus 28.4 % in group 2 and 46.9 % in group 
3 (p < .001). Moreover, 45.8 % of the patients in group 1 
were also attended in psychiatry versus 3 % in group 2 and 
15.6 % in group 3 (p < .001).
With respect to analgesics and NSAID, there were also 
differences between groups for all these drugs (Table 3). 
Major opioids were only consumed for patients in group 1 
(Table 3).
With respect to drugs used for treating other comorbidi-
ties, group 1 received more drugs and there was no differ-
ence between groups 2 and 3 (Table 4). Gastric protectors, 
vitamin D supplements, antimigraine agents, lactose-free 
diet and betahistine for dizziness were more common in 
group 1, while biphosphonates were more common in 
group 2.
In the total number of patients, there was a positive cor-
relation between the use of gastric protectors and the num-
ber of drugs consumed for treating all comorbidities (rho 
Spearman = 0.648, p < .0001).
The duration of the treatments for all types of comor-
bidities was significantly longer in group 1 than in the two 
other groups. There were no differences between groups 2 
and 3 (see Tables 2, 3, 4).
The analysis of the duration of all types of treat-
ments in patients of group 1 showed that benzodiazepines, 
Table 2  Drugs for treating NS comorbidities
Group 1 (FM/FM): diagnosis of FM and fulfilling ACR criteria; group 2 (noFM/noFM): other diagnosis and not fulfilling ACR criteria; group 3 
(noFM/FM): other diagnosis and fulfilling ACR criteria
ns non-significant
Post hoc analysis: (a) significant difference between groups 1 and 2; (b) significant difference between groups 2 and 3; (c) significant difference 
between groups 1 and 3. Significant values at p < .05
Group 1
FM/FM
Number of patients (%)
Group 2
noFM/noFM
Number of patients (%)
Group 3
noFM/FM
Number of patients (%)
Difference between groups
p
Benzodiazepines and hypnotics 43 (72.9)(a) 14 (20.9)(b) 13 (40.6)(b) <.001
Antidepressants 38 (62.7)(a) 8 (11.9) 5 (15.6)(b) <.001
Anticonvulsants 19 (32.2)(a) 1 (1.5)(b) 5 (15.6) <.001
Antipsychotics 3 (5.1) 1 (1.5) 1 (3.1) ns
Duration in months
(mean ± SD)
94.22 ± 100.01(a) 25.19 ± 72.98 40.40 ± 77.89(c) <.001









Table 3  Analgesics and NSAID
Group 1 (FM/FM): diagnosis of FM and fulfilling ACR criteria; group 2 (noFM/noFM): other diagnosis and not fulfilling ACR criteria; group 3 
(noFM/FM): other diagnosis and fulfilling ACR criteria
(¶) Duration for tramadol and major opioids
Post hoc analysis: (a) significant difference between groups 1 and 2; (b) significant difference between groups 2 and 3; (c) significant difference 
between groups 1 and 3. Significant values at p < .05
Group 1
FM/FM
Number of patients (%)
Group 2
noFM/noFM
Number of patients (%)
Group 3
noFM/FM
Number of patients (%)
Difference between groups
p
NSAID 40 (67.8)(a) 13 (19.4) 9 (28.1)(c) <.001
Common analgesics 35 (59.3)(a) 20 (29.9) 16 (50.0) <.003
Tramadol + paracetamol 8 (13.6)(a) 2 (3.0) 1 (3.1) <.042
Tramadol 6 (10.2)(a) 0 (0.0)(b) 4 (12.5) <.018
Major opioids 8 (13.6)(a) 0 (0.0) 0 (0.0)(c) <.001
Duration in months(¶) (mean ± SD) 5.28 ± 16.03(a) 0.0 ± 0.0 1.40 ± 5.42 <.05
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antidepressants and anticonvulsants had a shorter median dura-
tion than other drugs for treating other comorbidities (Table 5).
With respect to the analysis of the severity of comor-
bidities, there was no significant difference between groups 
in the number of severe comorbidities. The comparison 
between the number of appropriate treatments in severe 
comorbidities also showed no significant differences 
between groups (Table 6).
However, in the case of mild comorbidities, there was a 
significant difference between groups with a greater num-
ber of comorbidities in patients of group 1 (Table 6). More-
over, the number of appropriate treatments was also signifi-
cantly different with more unjustified treatments in group 
1 versus the two other groups. There were no differences 
between groups 2 and 3 (Table 6).
Discussion
The types of comorbidities found in patients with FM were 
similar to the ones in the control patients without FM. The 
most relevant differences were the higher number and the 
longer duration of the treatments found in patients with FM 
in this study.
Drugs for treating NS comorbidities, migraines, dizzi-
ness, gastric protectors and the use of analgesics were more 
common in patients with FM, as described in previous 
studies [7], but these clinical conditions are also commonly 
present in many patients without FM.
Drugs for treating potential severe comorbidities such 
as high blood pressure, hypothyroidism or high cholesterol 
levels were the same as in controls without FM showing 
Table 4  Drugs, supplements and other measures for treating other comorbidities
Group 1 (FM/FM): diagnosis of FM and fulfilling ACR criteria; group 2 (noFM/noFM): other diagnosis and not fulfilling ACR criteria; group 3 
(noFM/FM): other diagnosis and fulfilling ACR criteria
Post hoc analysis: (a) significant difference between groups 1 and 2; (b) significant difference between groups 2 and 3; (c) significant difference 
between groups 1 and 3. Significant values at p < .05
ns non-significant, Supp. supplements, SYSADOA symptomatic slow action drugs for osteoarthritis
(¶) Between parents, means number of patients treated. Folic acid supp. (4), metoclopramide (3), beta blockers (3), nasal decongestants (3), con-
tinuous positive airway pressure (CPAP) (2), antispasmodics (2), diuretics (2), acetylsalicylic acid (2), hormone replacement therapy (2), fruc-
tose-free diet (1), diosmin (1), carbamazepine (1), tamoxifene (1), Q10 supp. (1), rotigotine (1), clebopride (1), hydroaltesone (1), tranexamic 
acid (1), ursodeoxycholic acid (1), sibutramine (1), calcitonin (1), salazopyrin (1)
Group 1
FM/FM
Number of patients (%)
Group 2
noFM/noFM
Number of patients (%)
Group 3
noFM/FM
Number of patients (%)
Difference between groups
p
Gastric protectors 36 (61.0)(a) 12 (17.9)(b) 15 (46.9) <.001
Thyroid hormone 9 (15.3) 13 (19.4) 6 (18.8) ns
Antihypertensive 14 (23.7) 10 (14.9) 4 (14.5) ns
Vitamin D supp. 15 (25.4)(a) 5 (7.5) 3 (9.4) <.011
Statins 6 (10.2) 11 (16.4) 6 (18.8) ns
Calcium + Vit.D supp. 6 (10.2) 12 (17.9) 4 (12.5) ns
Bronchodilators 6 (10.2) 2 (3.0) 3 (9.4) ns
Antimigraine agents 7 (11.9)(a) 1 (1.5) 1 (3.1) <.034
Antidiabetics 4 (6.8) 4 (6.0) 1 (3.1) ns
Bisphosphonates 1 (1.7)(a) 7 (10.5) 0 (0.0) <.028
Polivitamins supp. 5 (8.5) 1 (1.5) 2 (6.3) ns
Antihistamines 3 (5.1) 2 (3.0) 3 (9.4) ns
Iron supp. 3 (5.1) 1 (1.5) 2 (6.3) ns
SYSADOA 5 (8.5) 0 (0,0) 1 (3.1) <.045
Domperidone 4 (6.8) 0 (0,0) 1 (3.1) ns
Gluten-free diet 4 (6.8) 1 (1.5) 0 (0.0) ns
Lactose-free diet 4 (6.8)(a) 0 (0.0) 0 (0.0) <.032
Betahistine 4 (6.8)(a) 0 (0.0) 0 (0.0) <.032
Various(¶) 24 8 4 –
Duration in months (mean ± SD) 154.03 ± 180.10(a) 71.46 ± 105.67 112.78 ± 206.11 <.016
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that these types of comorbidities are not increased in FM 
patients. Similar findings were found in a recent systematic 
revision [17] where the presence of severe comorbidity in 
FM was analysed but no clear association was found.
However, drugs for treating mild comorbidities such as 
vitamin D or other vitamins, iron, folic, Q10 deficiencies, 
coeliac disease and lactose intolerance were found signifi-
cantly more frequent in patients with FM. It is known that 
Table 5  Duration in months 
of different treatments in 
patients of group 1 (FM/
FM). Benzodiazepines, 
antidepressants and 
anticonvulsants are in bold in 
the table. Only those treatments 
administered to three or more 
patients are shown in the table
Number of patients  
with treatment
Duration of treatment in 
months (mean ± SD)
Thyroid hormone 9 152.00 ± 116.34
Lactose-free diet 4 137.00 ± 168.48
Gluten-free diet 4 114.00 ± 164.68
Polivitamins supp. 5 84.80 ± 155.00
Betahistine 4 78.25 ± 74.59
Antidiabetics 4 74.75 ± 52.72
Bronchodilators 6 71.00 ± 38.77
Gastric protectors 35 69.40 ± 65.93
Benzodiazepines 43 66.55 ± 73.09
Statins 6 66.00 ± 31.06
Antidepressants 37 53.89 ± 53.34
Antihypertensives 14 50.28 ± 47.51
Calcium + Vit.D supp. 6 43.50 ± 44.24
Domperidone 4 42.00 ± 28.56
Antimigraine agents 7 40.71 ± 35.80
Anticonvulsants 19 37.00 ± 38.55
Folic acid supp. 3 29.00 ± 23.30
Antihistamines 3 17.16 ± 26.73
Vitamin D supp. 15 16.40 ± 20.77
SYSADOA 5 13.10 ± 20.01
Iron supp. 3 5.66 ± 5.50
Major opioid 6 4.00 ± 15.33
Tramadol 5 1.29 ± 5.69
Table 6  Types of comorbidities and appropriateness of the treatments
Group 1 (FM/FM): diagnosis of FM and fulfilling ACR criteria; group 2 (noFM/noFM): other diagnosis and not fulfilling ACR criteria; group 3 
(noFM/FM): other diagnosis and fulfilling ACR criteria
ns non-significant
Post hoc analysis: (a) significant difference between groups 1 and 2; (b) significant difference between groups 2 and 3; (c) significant difference 
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the prescription of these types of treatment depends on the 
facultative criteria and it is not usually based on clinical 
practice guidelines recommendations.
The difference between comorbidity and symptom is 
not well defined [18]. Most drugs consumed by patients 
with FM are prescribed for treating symptoms that are 
inherent to the principal clinical picture of FM and for 
this reason they are not considered as comorbidities by 
some authors [4]. Positive correlation found in this study 
between somatic symptoms and the number of drugs pre-
scribed indicates that the more symptomatic the disease is 
the higher is the number of drugs prescribed.
For example, in rheumatoid arthritis the extra-articular 
manifestations are considered as clinical manifestations by 
some authors or as comorbidities by others [19]. The treat-
ment used to be almost the same. However, considering 
clinical manifestations as symptoms or as comorbidities in 
FM—a multisymptomatic disease—can have considerable 
consequences. In the first case, the main treatment of FM 
can be sufficient to improve symptoms but, in the second 
case, the probability of prescribing new drugs is high.
Separate treatment of clinical manifestations does not 
guarantee an improvement in the disease and may increase 
the risk of drug interactions and adverse events adding 
more clinical manifestations or aggravating them [7]. Some 
studies have shown that some clinical manifestations such 
as dizziness—a common symptom in patients with FM—
are positively correlated with the number of consumed 
drugs [20].
Positive correlation between the use of gastric protectors 
and the total drugs consumed by our patients probably indi-
cate the need to add more drugs to prevent complications 
when many other treatments are already used. This clearly 
contributes to increase polymedication.
Opioids prescription in patients with FM has increased 
drastically over the past years. However, it is well known 
that opioid prescribing decision is not based only on 
patient–physician interaction but also on other factors that 
may explain the wide geographic variation found in some 
studies [21].
In our study, 13.6 % of patients with FM were tak-
ing major opioids and 74 % consumed benzodiazepines. 
Recently, it has been shown that combined consumption 
of these two drugs clearly increases the risk of serious 
interactions and can multiply by 15 the risk of death [22]. 
Although there is no conclusive evidence against these two 
drugs in the treatment of FM, recent clinical guidelines in 
FM advise against their use by their deleterious adverse 
events [23, 24].
Psychiatric symptoms are very frequent and may be 
seen in two-thirds of the patients with FM, mostly depres-
sive syndromes [25]. The question of whether psychiatric 
symptoms precede the development of FM or appear along 
the course of the disease is frequently considered and 
does not have a good answer. But it is a very important 
issue when planning the treatment and follow-up of these 
patients.
Treatment with benzodiazepines and antidepressants has 
a shorter duration than with other drugs in this study, and 
they are prescribed when other comorbidities are already 
being treated. Additionally, 45 % of patients with a previous 
diagnosis of FM (group 1) versus 15 % of the patients with 
other diagnosis but fulfilling ACR criteria for FM (group 
3) were also attended by psychiatrists. These data suggest 
that psychiatric comorbidity appears later in the course of 
the disease when other comorbidities and treatments have 
already started. It also means that in multisymptomatic 
patients an early psychological therapy focused on relaxa-
tion techniques, learning and acquisition of adequate cop-
ing strategies to manage initial somatic manifestations may 
be a great help to reduce NS drugs [26].
The appropriateness of the severe comorbidity treat-
ments has shown that criteria for treatment were well estab-
lished following clinical practice guidelines. However, for 
mild comorbidities, patients with FM received a greater 
number of treatments which were not well justified. This 
means that some drugs used for treating some clinical 
symptoms should be eliminated.
Patients’ demand for an efficient solution of their 
symptoms put a lot of pressure on the attending physician. 
In the absence of more appropriate resources—such as the 
psychological therapy mentioned before—the option of a 
drug prescription is an evident risk that should be avoided 
[27, 28].
Those patients who had not been previously diagnosed 
of FM but fulfilled ACR criteria (group 3) present some 
interesting features. The total number of drugs consumed, 
duration of treatments, presence of mild comorbidities and 
treatment appropriateness are the same as those of patients 
that do not have FM (group 2). Moreover, in this group, the 
analysis of the duration of the different treatments shows 
that benzodiazepines are the first drug prescribed for treat-
ing NS comorbidity.
This group is also interesting because it is composed 
of patients in the initial phases of the disease. On the one 
hand, they have many somatic symptoms and may be 
diagnosed of FM, but, on the other hand, they are not still 
treated with many drugs. Identifying these patients is very 
important in order to control the evolution of the disease 
and to avoid unnecessary use of drugs and their negative 
consequences.
In rheumatoid arthritis, some recommendations for 
treatment and control of the comorbidities have been 
recently established, due to the increased mortality risks 
1698 Rheumatol Int (2016) 36:1691–1699
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[19]. In the case of FM, establishing treatment crite-
ria and recommendations for somatic symptoms and 
other comorbidities is also important, in this case to 
avoid polimedication, drug interactions and symptoms 
exacerbation.
This study has several limitations. The cross-sectional 
design of the study describes the situation of the patients 
compared with that of controls, but it does not shed light on 
the origin or the consequences of the problem. The lack of 
a control group with individuals of the general population 
does not allow a better evaluation of the drugs prescribed 
for treating comorbidities in these patients.
The fact that this study has been performed in only one 
centre specialized in FM management does not allow to 
generalize the results to other primary care centres or other 
types of patients.
The strong point of the paper is that its design and 
results allow a clear visualization of the FM spectrum, from 
mild clinical pictures with the possibility of early interven-
tions and possible prevention up to severe cases.
Conclusions
The types of comorbidities in patients with FM are simi-
lar to the ones presented by other patients without the dis-
ease. The main differences are quantitative, patients with 
FM received more drugs and for a longer period of time for 
treating these comorbidities.
Drugs for treating NS comorbidities appear later, when 
other somatic symptoms are already treated. There are also 
mild comorbidities where the treatment with drugs is not 
well justified.
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